FibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval

Reuters

2025/07/09

<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval

FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell™, an investigational cell therapy aimed at treating degenerative disc disease $(DDD)$. This development allows the company to proceed with amending its Investigational New Drug $(IND.AU)$ clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491609-en) on July 09, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550963794"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550963794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550963794?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550963794","market":"fut","top_or_hot":-1,"title":"FibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell™, an investigational cell therapy aimed at treating degenerative disc disease <a href=\"https://laohu8.com/S/DDD\">$(DDD)$</a>. This development allows the company to proceed with amending its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491609-en) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-09 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell™, an investigational cell therapy aimed at treating degenerative disc disease <a href=\"https://laohu8.com/S/DDD\">$(DDD)$</a>. This development allows the company to proceed with amending its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491609-en) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL4KT6GS:1","article_id":"2550963794","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550963794","pubTimestamp":1752064266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell Manufacturing Approval. FibroBiologics, Inc. , a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell, an investigational cell therapy aimed at treating degenerative disc disease . This development allows the company to proceed with amending its Investigational New Drug  clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.Disclaimer: This news brief was created by Public Tech","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","FBLG":"FibroBiologics","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"FibroBiologics Inc.宣布CybroCell治疗退行性椎间盘疾病的临床试验取得进展™生产批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBLG":0.9,"NDAQ":0.9},"content_text":"FibroBiologics Inc. Announces Advancement in Clinical Trial for Degenerative Disc Disease with CybroCell™ Manufacturing Approval\n    \n\n        FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell™, an investigational cell therapy aimed at treating degenerative disc disease $(DDD)$. This development allows the company to proceed with amending its Investigational New Drug $(IND.AU)$ clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491609-en) on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}